Clinical trials: Frequency Lowering
Urinary Bladder, Overactive
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
- Trial name
- ARIES (NCT00662909)
- Testing
- Mirabegron
- Where
- 125 sites in United States, Canada
- Volunteers
- 2,149 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
The purpose of this study is to evaluate the change from baseline between the active and sham treatment groups in the treatment of urgency (urinary) incontinence episodes (leaks).
- Trial name
- Beacon (NCT01369485)
- Testing
- (VERV™ System)
- Where
- 14 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ethicon Endo-Surgery
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
- Trial name
- NCT01286454
- Testing
- fesoterodine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Failed Back Surgery Syndrome, Complex Regional Pain Syndrome (CRPS)
A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain
This study is a prospective, single-arm, open label, single center pilot study to confirm the safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The actual trial length is 5 days.
- Trial name
- NCT03285113
- Testing
- GiMer Medical MN 1000 External Stimulator
- Where
- Taiwan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GiMer Medical
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
- Trial name
- CAPRICORN (NCT00912964)
- Testing
- Mirabegron
- Where
- 151 sites in United States, Canada and 9 more
- Volunteers
- 2,030 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Urgency-frequency, Overactive Bladder
InSite for Over Active Bladder
The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2.
- Trial name
- InSite - OAB (NCT00547378)
- Testing
- InterStim, Standard Medical Therapy
- Volunteers
- 571 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Urge Urinary Incontinence, Urinary Frequency
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
The primary objective of the double-blind phase of the study is to compare the effects of two doses of oxybutynin gel to placebo gel.
- Trial name
- NCT00909181
- Testing
- Oxybutynin
- Where
- 55 sites in United States
- Volunteers
- 626 people
- Sponsor
- Antares Pharma Inc.
Urgency Frequency, Urinary Urge Incontinence
InterStim Therapy Programming Study
This study assessed the effect of different InterStim rate settings on voiding diary outcomes. Specifically, the study evaluated how 3 different rate settings affected the number of urinary incontinent episodes per day collected…
- Trial name
- NCT01009333
- Testing
- InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MedtronicNeuro
Urologic Diseases, Urinary Bladder, Overactive
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of…
- Conditions
- Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
- Trial name
- BEYOND (NCT01638000)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 217 sites in Armenia, Austria and 31 more
- Volunteers
- 1,887 people
- Sponsor
- Astellas Pharma Europe Ltd.
Overactive Bladder
Overactive Bladder Innovative Therapy Trial (OrBIT)
The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).
- Trial name
- OrBIT (NCT00448175)
- Testing
- Urgent PC Neuromodulation System, Tolterodine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Uroplasty, Inc
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
This pilot clinical study, which focuses on feasibility and proof-of-principle, will be conducted in 11 female subjects (55-100 years old) with UI.
- Trial name
- OAB Aim 2 (NCT03595215)
- Testing
- TENS
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
Overactive Bladder
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.
- Trial name
- NCT01125722
- Testing
- Non-invasive neurostimulation device
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 74 people
- Sponsor
- Ethicon Endo-Surgery
Pain, Chronic, Pain, Back
Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain
This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain.
- Conditions
- Pain, Chronic, Pain, Back, Pain, Radiating
- Trial name
- NCT03543085
- Testing
- GiMer Medical MN 1000 External Stimulator
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- GiMer Medical